## Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claim 1 (currently amended) Monoclonal antibody directed against the ~~G3BP~~ protein of SEQ ID NO:1 and capable of inducing apoptosis in various types of tumor cells, wherein the antibody recognizes an epitope between amino acids 1 and 144 of SEQ ID NO:1.

Claim 2 (canceled)

Claim 3 (currently amended) Monoclonal antibody according to ~~claim 1 or 2~~ claim 1, capable of recognizing an epitope between ~~the amino acids situated at positions~~ amino acids 1 to 72 of ~~the G3BP protein~~ SEQ ID NO:1~~, preferably an epitope between the amino acids situated at positions 22 to 55 of the G3BP protein, and preferably still an epitope consisting of the amino acids situated at positions 22 to 34~~.

Claim 4 (currently amended) ~~Antibody according to claims 1 to 3, characterized in that it is the~~ The antibody Mab 1F1, secreted by the hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the number I-2038.

Claim 5 (withdrawn) Use of an antibody according to one of claims 1 to 4 for obtaining a medicine.

Claim 6 (withdrawn) Use of an antibody according to one of claims 1 to 4 for obtaining a medicine intended for the treatment or prevention of hyperproliferative disorders.

Claim 7 (currently amended) Pharmaceutical composition comprising a therapeutically effective quantity of the monoclonal antibodies according to ~~one of claims 1 to 4~~ claim 1~~, optionally mixed with a pharmaceutically acceptable carrier,~~ the said quantity being therapeutically effective for inducing apoptosis in tumor cells.

Claim 8 (currently amended) Hybridoma line capable of secreting monoclonal antibodies according to ~~one of claims 1 to 4~~ claim 1.

Claim 9 (original) Hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the deposit number I-2038.

Claim 10 (withdrawn) Method of producing monoclonal antibodies capable of inducing apoptosis in various tumour lines, characterized in that it comprises (1) the fusion of spleen cells from an animal immunized with the aid of the G3BP protein or of a fragment comprising at least a portion of the N-terminal domain (aa 1-144), with myelomatous cells under conditions allowing the formation of hybridomas; (2) the detection and isolation of those of the said hybridomas which secrete monoclonal antibodies capable of inducing apoptosis in various tumour lines.

Claim 11 (withdrawn) Use of an antibody according to one of claims 1 to 4, as diagnostic reagent.

Claim 12 (canceled)

Claim 13 (new) Monoclonal antibody according to claim 3, capable of recognizing an epitope between amino acids 22 to 55 SEQ ID NO:1.

Claim 14 (new) Monoclonal antibody according to claim 13, capable of recognizing an epitope between amino acids 22 to 34 SEQ ID NO:1.